SEC Form 4 · accession 0001209191-16-149542

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Nov 9, 2016

Accepted (ET)

Nov 14, 2016 · 8:41 am EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Nov 9, 2016	M	6,500	$36.30	A	274,725	D
Common Stock^F2,F3	Nov 9, 2016	S	800	$88.48	D	273,925	D
Common Stock^F2,F4	Nov 9, 2016	S	1,900	$90.13	D	272,025	D
Common Stock^F2,F5	Nov 9, 2016	S	1,500	$91.11	D	270,525	D
Common Stock^F2,F6	Nov 9, 2016	S	1,400	$92.10	D	269,125	D
Common Stock^F2,F7	Nov 9, 2016	S	900	$93.04	D	268,225	D
Common Stock	holding	—	—		—	13,286	I	401(k)
Common Stock	holding	—	—		—	78,200	I	Common Stock Held In Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F8	$36.30	Nov 9, 2016	M	6,500	D	—	Jan 23, 2017	Common Stock	6,500	60,000	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $88.48 (range $88.18 to $89.00).
F4Open market sales reported on this line occurred at a weighted average price of $90.13 (range $89.59 to $90.49).
F5Open market sales reported on this line occurred at a weighted average price of $91.11 (range $90.73 to $91.60).
F6Open market sales reported on this line occurred at a weighted average price of $92.10 (range $91.73 to $92.72).
F7Open market sales reported on this line occurred at a weighted average price of $93.04 (range $92.84 to $93.47).
F8Fully vested.